Oculis to Present New Neuro-Ophthalmic Drug at Summit 2026
Oculis Holding AG, a global biopharmaceutical company based in Zug, Switzerland, will present its breakthrough neuro-ophthalmology drug Privosegtor during upcoming clinical trials at the Summit 2026. This announcement highlights Oculis' ongoing efforts to address significant unmet medical needs in ophthalmology and neuro-ophthalmology.